Table of Contents
International Journal of Molecular Imaging
Volume 2011, Article ID 524130, 7 pages
http://dx.doi.org/10.1155/2011/524130
Research Article

Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT

1Department of Nuclear Medicine, College of Medicine, Seoul National University, Seoul 151-742, Republic of Korea
2Department of Nuclear Medicine, Center for PET/CT, Zentralklinik Bad Berka, Robert Koch Allee 9, 99437 Bad Berka, Germany

Received 25 May 2011; Revised 10 August 2011; Accepted 18 August 2011

Academic Editor: Xiaoyuan Chen

Copyright © 2011 Sowon Oh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. T. Barakat, K. Meeran, and S. R. Bloom, “Neuroendocrine tumours,” Endocrine-Related Cancer, vol. 11, no. 1, pp. 1–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. I. M. Modlin, K. Mark, I. Latich, M. N. Zikusoka, and M. D. Shapiro, “Current status of gastrointestinal carcinoids,” Gastroenterology, vol. 128, no. 6, pp. 1717–1751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. G. A. Kaltsas, G. Besser, and A. B. Grossman, “The diagnosis and medical management of advanced neuroendocrine tumors,” Endocrine Reviews, vol. 25, no. 3, pp. 458–511, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Oberg and B. Eriksson, “Medical treatment of neuroendocrine gut and pancretic tumors,” Acta Oncologica, vol. 28, no. 3, pp. 425–431, 1989. View at Google Scholar · View at Scopus
  5. D. J. Kwekkeboom, E. P. Krenning, R. Lebtahi et al., “ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs,” Neuroendocrinology, vol. 90, no. 2, pp. 220–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. L. K. Kvols, C. Moertel, and M. J. O'Connell, “Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue,” The New England Journal of Medicine, vol. 315, no. 11, pp. 663–666, 1986. View at Google Scholar · View at Scopus
  7. A. Rinke, H. H. Muller, C. Schade-Brittinger et al., “Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4656–4663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Faiss, U. Pape, M Bohmig et al., “Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, inteferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the international lanreotide and interferon alfa study group,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2689–2696, 2003. View at Google Scholar
  9. E. T. Janson and K. Oberg, “Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with α-interferon,” Acta Oncologica, vol. 32, no. 2, pp. 225–229, 1993. View at Google Scholar · View at Scopus
  10. F. Panzuto, M. Di Fonzo, E. Iannicelli et al., “Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma,” Annals of Oncology, vol. 17, no. 3, pp. 461–466, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Shojamanesh, F. Gibril, L. Adeline et al., “Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma,” Cancer, vol. 94, no. 2, pp. 331–343, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Buchmann, M. Henze, S. Engelbrecht et al., “Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 10, pp. 1617–1626, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Hofmann, H. Maecke, A. Borner et al., “Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data,” European Journal of Nuclear Medicine, vol. 28, no. 12, pp. 1751–1757, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Kowalski, M. Henze, J. Schuhmacher, R. M. Helmut, H. Michael, and H. Uwe, “Evaluation of positiron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors,” Molecular Imaging & Biology, vol. 5, no. 1, pp. 42–48, 2003. View at Publisher · View at Google Scholar
  15. D. J. Kwekkeboom, W. Bakker, B. L. Kam et al., “Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 3, pp. 417–422, 2003. View at Google Scholar · View at Scopus
  16. D. J. Kwekkeboom, W. W. de Herder, B. L. Kam et al., “Treatment with the radiolabled somatostatin analog [177Lu-DOTAo,Tyr3] octreotate: toxicity, efficacy and survival,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2124–2130, 2008. View at Google Scholar
  17. A. R. Haug, C. J. Auernhammer, G. P. Schmidt et al., “68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors,” Journal of Nuclear Medicine, vol. 51, no. 9, pp. 1349–1356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Asnacios, F. Courbon, P. Rochaix et al., “Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors,” Journal of Clinical Oncology, vol. 26, no. 6, pp. 963–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Wild, J. S. Schmitt, M. Ginj et al., “DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 10, pp. 1338–1347, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Adams, R. Baum, T. Rink, and K. H. Usadel, “Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours,” European Journal of Nuclear Medicine, vol. 25, no. 1, pp. 79–83, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Pasquali, D. Rubello, C. Sperti et al., “Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?” World Journal of Surgery, vol. 22, no. 6, pp. 588–592, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Koukouraki, L. G. Strauss, V. Georgoulias, M. Eisenhut, U. Haberkorn, and A. Dimitrakopoulou-Strauss, “Comparison of the pharmacokinetics of 68Ga-DOTATOC and [ 18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 10, pp. 1115–1122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Kayani, J. B. Bomanji, A. Groves et al., “Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (Dota-DPhe1, Tyr3-octreotate) and 18F-FDG,” Cancer, vol. 112, no. 11, pp. 2447–2455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. P. Zhernosekov, D. V. Filosofov, R. P. Baum et al., “Processing of generator-produced 68Ga for medical application,” Journal of Nuclear Medicine, vol. 48, no. 10, pp. 1741–1748, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. G. J. Meyer, J. Schuhmacher, W. H. Knapp, and M. Hofmann, “68Ga-labelled DOTA-derivatised peptide ligands,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 8, pp. 1097–1104, 2004. View at Google Scholar · View at Scopus
  26. I. Virgolini, V. Ambrosini, J. B. Bomanji et al., “Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 10, pp. 2004–2010, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Boellaard, M. J. O'Doherty, W. A. Weber et al., “FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 1, pp. 181–200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. R. P. Baum, V. Prasad, M. Hommann, and D. Horsch, “Receptor PET/CT imaging of neuroendocrine tumors,” Recent Results in Cancer Research. Fortschritte der Krebsforschung, vol. 170, pp. 225–242, 2008. View at Google Scholar · View at Scopus
  29. V. Prasad, V. Ambrosini, M. Hommann, D. Hoersch, S. Fanti, and R. P. Baum, “Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 1, pp. 67–77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Rimpler, I. Barth, R. B. Baum, S. Senftleben, and L. Geworski, “β radiation exposure of staff during and after therapies with 90Y-labelled substances,” Radiation Protection Dosimetry, vol. 131, no. 1, pp. 73–79, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. C. Reubi, L. K. Kvols, B. Waser et al., “Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas,” Cancer Research, vol. 50, no. 18, pp. 5969–5977, 1990. View at Google Scholar · View at Scopus
  32. D. J. Kwekkeboom, J. J. Teunissen, W. H. Bakker et al., “Radiolobeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2754–2762, 2005. View at Google Scholar
  33. R. P. Baum and V. Prasad, “Monitoring treatment,” in Clinical Nuclear Medicine, G. J. R. Cook, M. N. Maisey, K. E. Britton, and V. Chengazi, Eds., pp. 57–78, Hodder Arnold, London, UK, 4th edition, 2006. View at Google Scholar
  34. S. Ezziddin, M. Opitz, M. Attassi et al., “Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 3, pp. 459–466, 2010. View at Publisher · View at Google Scholar · View at Scopus